Anti-Inflammatory Dietary Supplements in Pregnancy: A Scoping Review
Nutrients · 31.10.2026 · 18 (21) · 3627
DOI: 10.3390/nu18213627 ↗Kurz gefasst
Scoping Review in der Zeitschrift Nutrients, online erschienen am 31.10.2026. Verfasst von Anamaria Apan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Physiology, Pathophysiology, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napo…. Hauptthemen laut MEDLINE: Dietary Supplements, Anti-Inflammatory Agents. Die Arbeit nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
This scoping review aimed to map the available evidence on the safety and efficacy of anti-inflammatory dietary supplements used during pregnancy, assessing maternal and fetal outcomes.
Methods
A systematic literature search was conducted in PubMed, Scopus, and Web of Science (January 2016–June 2026), following PRISMA-ScR guidelines. The protocol was prospectively registered on the Open Science Framework (10.17605/osf.io/4kmv9). Eligible studies included human clinical trials and observational studies evaluating anti-inflammatory dietary supplements in pregnant women.
Results
Eighty unique studies (96 publications) from 28 countries were included, of which 63 (78.8%) were randomized clinical trials. Thirteen supplement categories were identified. Vitamin D (n = 23) and omega-3 fatty acids (n = 17) accounted for nearly half of all studies; probiotics (n = 11) formed the third-largest category. For these three supplements, most studies reported changes in inflammatory and glycemic markers, primarily in gestational diabetes mellitus and high-risk populations, but adverse events were collected in a minority of studies, so tolerability is documented rather than established. Evidence for zinc, magnesium, and alpha-lipoic acid was limited. Curcumin, chlorella, vitamin E, epigallocatechin-3-gallate (EGCG), resveratrol, and ginger were each supported by only one or two studies. Supplementation was initiated in the first trimester in 19 studies (23.8%), and neonatal safety outcomes were reported infrequently.
Conclusions
Evidence on anti-inflammatory dietary supplements in pregnancy is concentrated in a few compounds, in a small number of countries, and in biochemical outcomes measured in selected populations. Tolerability was evaluated in only a small number of studies, which limits its use as an indicator of safety. The map highlights the scarcity of controlled studies with prespecified harm outcomes, of first-trimester initiation, and of infant follow-up beyond the first months of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Physiology, Pathophysiology, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
- HIVE Health Innovation Center, Babeș-Bolyai University, 400095 Cluj-Napoca, Romania.
- Department of Neurosciences-Psychiatry and Pediatric Psychiatry, Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
ORCID-Profile: Anamaria Apan, Cristina Pop, Oliviu Voștinaru, Maria Bonea, Cristina Mogoșan
Zitieren
APA
Apan, A., Pop, C., Iaru, I., Voștinaru, O., Cherecheș, R. M., Bonea, M., & Mogoșan, C. (2026). Anti-Inflammatory Dietary Supplements in Pregnancy: A Scoping Review. Nutrients, 18(21), 3627. https://doi.org/10.3390/nu18213627
Vancouver
Apan A, Pop C, Iaru I, Voștinaru O, Cherecheș RM, Bonea M, et al. Anti-Inflammatory Dietary Supplements in Pregnancy: A Scoping Review. Nutrients. 2026;18(21):3627. doi:10.3390/nu18213627
BibTeX
@article{Apan2026,
author = {Apan, Anamaria and Pop, Cristina and Iaru, Irina and Voștinaru, Oliviu and Cherecheș, Răzvan Mircea and Bonea, Maria and Mogoșan, Cristina},
title = {Anti-Inflammatory Dietary Supplements in Pregnancy: A Scoping Review},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {21},
pages = {3627},
doi = {10.3390/nu18213627}
}
EUVIMED